Article Text

OP0036 Fewer Patients on Biologicals and Better Functional Ability Two Years after Induction Therapy with Combination DMARD Therapy versus Methotrexate Monotherapy
  1. M. Kuijper1,
  2. A. Weel2,
  3. P. de Jong1,
  4. A. Gerards3,
  5. J. van Zeben4,
  6. I. Tchetverikov5,
  7. P. de Sonnaville6,
  8. M. van Krugten7,
  9. B. Grillet8,
  10. M. Hazes1,
  11. J. Luime1
  1. 1Rheumatology, Erasmus MC
  2. 2Rheumatology, Maasstad Hospital, Rotterdam
  3. 3Rheumatology, Vlietland Hospital, Schiedam
  4. 4Rheumatology, Sint Franciscus Gasthuis, Rotterdam
  5. 5Rheumatology, Albert Schweitzer Hospital, Dordrecht
  6. 6Rheumatology, Admiraal de Ruyter Hospital, Goes
  7. 7Rheumatology, Admiraal de Ruyter Hospital, Vlissingen
  8. 8Rheumatology, ZorgSaam Hospital, Terneuzen, Netherlands


Background Fewer patients on biologicals and better functional ability two years after induction therapy with combination DMARD therapy versus methotrexate monotherapy

Objectives To assess differences in frequency of biological therapy use in early RA patients two years after starting induction therapy according to three different treatment regimens

Methods Data were used from patients with recent-onset arthritis participating in a single-blinded clinical trial (Treatment in the Rotterdam Early Arthritis CoHort (tREACH)) [1,2] in which three induction therapy strategies were compared: (A) combination therapy (methotrexate (MTX) + sulfasalazine + hydroxychloroquine) with glucocorticoids (GCs) intramuscularly; (B) combination therapy with an oral GC tapering scheme and (C) MTX with oral GCs similar to B. Disease activity scores (original DAS) were assessed every 3 months. Functional ability was assessed using the Health assessment questionnaire (HAQ). Actual medication use was obtained from medical charts and from patient diaries. Data were analysed using simple descriptive statistical techniques.

Results 281 patients (91 men, 190 women; mean baseline DAS 3.4, median baseline HAQ 0.75) were initially randomized. Data on medication use at 2 years were available from 166 patients (59%). Mean DAS was 1.72 (95%CI 1.59-1.86) at 24 months with similar results for the initial treatment groups A-C. DAS remission (DAS<1.6) was achieved by 50% of patients. Median HAQ (min-max) was 0.38 (0-2) for all patients but varied in the treatment groups: A. 0.13 (0-1.6), B. 0.44 (0-2) and C. 0.63 (0-2). HAQ was significantly higher in group C versus A (p=0.042), while no significant difference was observed for group A versus B (p=0.39).

Conventional DMARDs only were used in 58% of patients (A. 60%, B. 75% and C. 43%). Biological DMARDs only were used in 5% of patients (A. 8%, B. 2% and C 7.%). Thirteen percent of patients did not use any DMARD at all (A. 14%, B. 9% and C. 16%). Patients in group C used biological DMARDs more often compared to B (p=0.004), but no statistical difference was observed between groups A and B (p=0.241).

Conclusions We observed lower use of biological therapy and better functional ability in induction triple therapy compared to induction monotherapy MTX with GC bridging at 2 years of follow-up in the treat-to-target tREACH study. No differences were found for disease activity scores.


  1. Claessen et al. Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. BMC Musculoskelet Disord 2009;10:71.

  2. De Jong et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013 Jan;72(1):72-8.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.5357

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.